Page 1694 - Williams Hematology ( PDFDrive )

1668 Part XI: Malignant Lymphoid Diseases Chapter 101: Marginal Zone B-cell Lymphomas 1669

30. Vanazzi A, Grana C, Crosta C, et al: Efficacy of Yttrium-ibritumomab tiuxetan in 39. Tsimberidou AM, Catovsky D, Schlette E, et al: Outcomes in patients with splenic mar-
90
relapsed/refractory extranodal marginal-zone lymphoma. Hematol Oncol 32:10–15, 2014. ginal zone lymphoma and marginal zone lymphoma treated with rituximab with or
31. Boveri E, Arcaini L, Merli M, et al: Bone marrow histology in marginal zone B-cell without chemotherapy or chemotherapy alone. Cancer 107:125–135, 2006.
lymphomas: Correlation with clinical parameters and flow cytometry in 120 patients. 40. Bennett M, Sharma K, Yegena S, et al: Rituximab monotherapy for splenic marginal
Ann Oncol 20:129–136, 2009. zone lymphoma. Haematologica 90:856–858, 2005.
32. Zibellini S, Capello D, Forconi F, et al: Stereotyped patterns of B-cell receptor in splenic 41. Lefrère F, Hermine O, Belanger C, et al: Fludarabine: An effective treatment in patients
marginal zone lymphoma. Haematologica 95:1792–1796, 2010. with splenic lymphoma with villous lymphocytes. Leukemia 14:573–575, 2000.
33. Traverse-Glehen A, Verney A, Baseggio L, et al: Analysis of BCL-6, CD95, PIM1, RHO/ 42. Cheson BD, Friedberg JW, Kahl BS, et al: Bendamustine produces durable responses
TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas sug- with an acceptable safety profile in patients with rituximab refractory indolent non-
gests a particular B-cell origin. Leukemia 21:1821–1824, 2007. Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10:452–457, 2010.
34. Hermine O, Lefrère F, Bronowicki JP, et al: Regression of splenic lymphoma with villous 43. Arcaini L, Lazzarino M, Colombo N, et al: Splenic marginal zone lymphoma: A prog-
lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347:89–94, 2002. nostic model for clinical use. Blood 107:4643–4649, 2006.
35. Salido M, Baro C, Oscier D, et al: Cytogenetic aberrations and their prognostic value 44. Brynes RK, Almaguer PD, Leathery KE, et al: Numerical cytogenetic abnormalities of
in a series of 330 splenic marginal zone B-cell lymphomas: A multicenter study of the chromosomes 3, 7, and 12 in marginal zone B-cell lymphomas. Mod Pathol 9:995–1000,
Splenic B-Cell Lymphoma Group. Blood 116:1479–1488, 2010. 1996.
36. Rossi D, Trifonov V, Fangazio M, et al: The coding genome of splenic marginal zone 45. Marasca R, Vaccai P, Luppi M, et al: Immunoglobulin gene mutations and frequent
lymphoma: Activation of NOTCH2 and other pathways regulating marginal zone use of VH1–69 and VH4–34 segments in hepatitis C virus-positive and hepatitis C
development. J Exp Med 209:1537–1551, 2012. virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 159:253–261, 2001.
37. Melo JV, Hegde U, Parreira A, et al: Splenic B cell lymphoma with circulating villous 46. Thieblemont C, Coiffier B: Management of marginal zone lymphomas. Curr Treat
lymphocytes: Differential diagnosis of B cell leukaemias with large spleens. J Clin Pathol Options Oncol 7:213–222, 2006.
40:642–651, 1987. 47. Vallisa D, Bernuzzi P, Arcaini L, et al: Role of anti-hepatitis C virus (HCV) treatment in
38. Thieblemont C, Felman P, Berger F, et al: Treatment of splenic marginal zone B-cell HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: A multicenter Italian expe-
lymphoma: An analysis of 81 patients. Clin Lymphoma 3:41–47, 2002. rience. J Clin Oncol 23:468–473, 2005.

Kaushansky_chapter 101_p1663-1670.indd 1669 9/18/15 9:37 AM